Altura Medical, Inc.

Canaccord Genuity acts as financial advisor to Altura Medical, Inc. on its sale to Lombard Medical, Inc.

Canaccord Genuity is pleased to announce that on July 30, 2015, Altura Medical, Inc., a medical device company developing a next generation endograft technology to treat abdominal aortic aneurysms and other disease states, completed its sale to Lombard Medical, Inc. (NSDQ:EVAR), a company specializing in endovascular stent-grafts for the repair of aortic aneurysms.  Lombard is issuing $15 million of its stock at $4 a share in connection with the deal, assuming $5.5 million of Altura bank debt, and assuming $2.5 million in certain liabilities and transaction-related costs.  In addition, up to $27.5 million may be paid based on the achievement of certain commercial and regulatory milestones, representing a total transaction value of up to $50.5 million.  Lombard plans to launch Altura’s low-profile endovascular stent graft technology in Europe early next year and recruit for a U.S. clinical study in late 2016.

Canaccord Genuity served as financial advisor to Altura and its Board of Directors in connection with the transaction.

Altura Medical is a private medical device company based in Silicon Valley that is developing a next generation endograft technology to treat abdominal aortic aneurysms (“AAA”) and other related disease states.  Development of the company’s highly differentiated technology is led by an experienced management team and supported by a strong syndicate of venture capital investors.

Lombard develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally.  The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of an abdominal aortic aneurysm with angulation at the neck of the aneurysm of up to 90 degrees.  It is also developing a stent-graft system to treat thoracic aortic aneurysms.  Lombard Medical sells its products directly through its direct sales force and third-party distributors.